53571-U

Ascentis^® Express 90 Å F5 (2.7 μm) HPLC Columns

L × I.D. 15 cm × 2.1 mm, HPLC Column

• 别名: Core-shell (SPP) Fused Core PFP HPLC column
• 分類程式碼代碼: 41115700
• eCl@ss: 32110501
• NACRES: SB.52

属性

• product name: Ascentis^® Express F5, 2.7 μm HPLC 色谱柱, 2.7 μm particle size, L × I.D. 15 cm × 2.1 mm
• 材料: stainless steel column
• agency: suitable for USP L43
• 產品線: Ascentis^®
• 特點: endcapped
• 製造商／商標名: Ascentis^®
• 包裝: 1 ea of
• 參數: 60 °C temp. range; 600 bar max. pressure (9000 psi)
• 技術: HPLC: suitable; LC/MS: suitable; UHPLC-MS: suitable; UHPLC: suitable
• 長度 × 內徑: 15 cm × 2.1 mm
• 表面積: 135 m²/g
• 雜質: <5 ppm metals
• 基質: Fused-Core particle platform; superficially porous particle
• 基質活性組: PFP (pentafluorophenyl) phase
• 粒徑: 2.7 μm
• 孔徑: 90 Å pore size
• 工作pH值: 2-8
• 應用: food and beverages
• 分離技術: reversed phase

说明

一般說明

由于存在电负性氟，Ascentis Express F5 的五氟苯基丙基固定相可提供具有缺电子苯环的稳定反相填料。除了形成 pi-pi 和温和的空间相互作用外，F5 相也通过极性相互作用保留化合物。Ascentis Express F5 可用于碱性、酸性或中性化合物，选择性与 C18 不同。

應用

• Liquid chromatographic determination of lumacaftor in the presence of ivacaftor and identification of five novel degradation products using high-performance liquid chromatography ion trap time-of-flight mass spectrometry.: This study employs the Ascentis^® Express F5, 2.7 μm HPLC Column to enhance the resolution and sensitivity in the analysis of lumacaftor and ivacaftor, critical medications for treating cystic fibrosis. The method provides significant insights into the stability and degradation pathways of these drugs, facilitating improved drug formulation and storage conditions (Ozcan et al., 2023).
• Stability-indicating LC-MS/MS and LC-DAD methods for robust determination of tasimelteon and high resolution mass spectrometric identification of a novel degradation product.: Utilizing the Ascentis^® Express F5, 2.7 μm HPLC Column, this research develops advanced analytical techniques for tasimelteon, a treatment for non-24-hour sleep-wake disorder. The methods ensure accurate quantification and stability assessment, crucial for clinical efficacy and patient safety (Ozcan et al., 2020).

法律資訊

Ascentis is a registered trademark of Merck KGaA, Darmstadt, Germany